peripheral T-cell lymphoma (Cancer)
Information
- Disease name
- peripheral T-cell lymphoma
- Disease ID
- DOID:0050749
- Description
- "A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus." [url:http\://en.wikipedia.org/wiki/Peripheral_T-cell_lymphoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04425070 | Active, not recruiting | Phase 1/Phase 2 | A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma | August 18, 2020 | December 31, 2024 |
| NCT04312841 | Active, not recruiting | Phase 2 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | September 15, 2020 | December 31, 2024 |
| NCT02232516 | Active, not recruiting | Phase 2 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | June 11, 2015 | August 2024 |
| NCT04480099 | Active, not recruiting | Phase 2 | Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | July 29, 2020 | April 2024 |
| NCT04447027 | Active, not recruiting | Phase 1 | Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies | December 17, 2020 | May 15, 2025 |
| NCT04569032 | Active, not recruiting | Phase 2 | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | November 12, 2020 | September 30, 2024 |
| NCT00072514 | Completed | Phase 2 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | August 2003 | November 2013 |
| NCT00078858 | Completed | Phase 1/Phase 2 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | September 2003 | |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00118352 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | March 2005 | May 26, 2015 |
| NCT00131937 | Completed | Phase 2 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | October 2005 | August 2012 |
| NCT00136565 | Completed | Phase 2 | Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma | January 8, 2006 | April 18, 2011 |
| NCT00337987 | Completed | Phase 2 | A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma | November 2005 | January 2008 |
| NCT00364923 | Completed | Phase 2 | Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | August 2006 | February 24, 2009 |
| NCT00406809 | Completed | Phase 1/Phase 2 | A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | November 2006 | October 2016 |
| NCT00426764 | Completed | Phase 2 | A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma | June 19, 2007 | May 17, 2018 |
| NCT00458731 | Completed | Phase 1 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | May 2007 | |
| NCT00481871 | Completed | Phase 1/Phase 2 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | May 2007 | August 2011 |
| NCT00536601 | Completed | N/A | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | June 29, 2006 | July 9, 2018 |
| NCT00571662 | Completed | Phase 2 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | December 8, 2000 | December 30, 2008 |
| NCT00644189 | Completed | Phase 1/Phase 2 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | June 2008 | July 2021 |
| NCT00705809 | Completed | T-Cell Project: Epidemiologic Component | June 18, 2008 | July 20, 2011 | |
| NCT00791947 | Completed | Phase 2 | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT | October 2001 | August 2010 |
| NCT00865969 | Completed | Phase 2 | Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma | December 15, 2008 | October 27, 2014 |
| NCT00888927 | Completed | Phase 1/Phase 2 | Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma | May 2009 | September 2012 |
| NCT00003196 | Completed | N/A | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | September 1997 | April 2002 |
| NCT00891072 | Completed | Phase 1 | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | July 2009 | April 2011 |
| NCT00930605 | Completed | Phase 2 | The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) | January 2005 | July 2008 |
| NCT01075321 | Completed | Phase 1/Phase 2 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | January 10, 2011 | February 13, 2020 |
| NCT01110135 | Completed | Phase 2 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | August 2010 | |
| NCT01110733 | Completed | Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry | February 2010 | December 2019 | |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT00006251 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | May 2000 | |
| NCT00014235 | Completed | N/A | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | December 2000 | |
| NCT00038025 | Completed | Phase 2 | A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies | September 6, 1994 | November 29, 2006 |
| NCT00040846 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | November 2001 | December 2009 |
| NCT00049504 | Completed | Phase 2 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | January 2002 | February 2014 |
| NCT01129180 | Completed | Phase 1 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | May 2010 | December 2012 |
| NCT01129193 | Completed | Phase 1 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | May 4, 2010 | January 7, 2017 |
| NCT01169298 | Completed | Phase 1 | A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma | July 1, 2010 | December 20, 2013 |
| NCT01177371 | Completed | Phase 2 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | March 1988 | February 2010 |
| NCT01226472 | Completed | Phase 2 | Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 | August 2010 | September 2012 |
| NCT01258998 | Completed | Phase 2 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | December 2010 | August 2015 |
| NCT01261247 | Completed | Phase 2 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | January 17, 2011 | December 2, 2019 |
| NCT01273766 | Completed | Phase 2 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | January 2011 | December 2014 |
| NCT01336920 | Completed | Phase 1 | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | June 21, 2011 | March 1, 2018 |
| NCT01336933 | Completed | Phase 2 | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | July 6, 2011 | December 28, 2016 |
| NCT01401530 | Completed | Phase 1 | E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma | July 2011 | January 2016 |
| NCT01427881 | Completed | Phase 2 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | September 2011 | July 2015 |
| NCT01435863 | Completed | Phase 1 | A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) | September 2011 | July 2015 |
| NCT01523223 | Completed | Phase 1 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | January 2012 | October 2016 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT01611142 | Completed | Phase 2 | Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) | April 2012 | May 2015 |
| NCT01614197 | Completed | Phase 1 | A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | July 3, 2015 | September 4, 2020 |
| NCT01658319 | Completed | Phase 1 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | May 2011 | May 2015 |
| NCT01664975 | Completed | Phase 4 | Treatment of Peripheral T-cell Lymphoma | August 2011 | April 2016 |
| NCT01689220 | Completed | Phase 1 | A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea | September 2012 | September 2014 |
| NCT01748721 | Completed | Phase 1 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2013 | May 2015 |
| NCT01767766 | Completed | Phase 1 | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | January 7, 2013 | February 2018 |
| NCT01796002 | Completed | Phase 3 | Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | January 2013 | December 13, 2022 |
| NCT01806337 | Completed | Phase 2 | CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma | July 2003 | February 2011 |
| NCT01822886 | Completed | Phase 2 | Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients | January 2013 | July 2018 |
| NCT01839097 | Completed | Phase 1 | Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) | May 2013 | January 2016 |
| NCT01839916 | Completed | Phase 2 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | April 4, 2013 | August 2018 |
| NCT01846390 | Completed | Phase 1 | Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma | October 1, 2013 | September 19, 2018 |
| NCT01959477 | Completed | Early Phase 1 | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant | March 2014 | April 2015 |
| NCT02013362 | Completed | Phase 1/Phase 2 | Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | March 2014 | September 2017 |
| NCT02142530 | Completed | Phase 1 | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | October 2014 | January 2018 |
| NCT02168140 | Completed | Phase 1 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | September 2014 | September 15, 2022 |
| NCT02264613 | Completed | Phase 1/Phase 2 | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | October 2014 | April 2020 |
| NCT02362997 | Completed | Phase 2 | Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL | April 2015 | June 2023 |
| NCT02653976 | Completed | Phase 2 | A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | March 25, 2016 | June 17, 2021 |
| NCT02676778 | Completed | Phase 2 | Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma | March 28, 2016 | April 26, 2019 |
| NCT02809573 | Completed | Phase 1 | Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients | August 11, 2016 | January 8, 2019 |
| NCT03212937 | Completed | Phase 1 | Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma | July 1, 2016 | November 2020 |
| NCT03372057 | Completed | Phase 2 | A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | February 22, 2018 | December 22, 2023 |
| NCT04858568 | Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients | March 11, 2021 | January 31, 2024 | |
| NCT05458180 | Not yet recruiting | Phase 1 | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | July 7, 2022 | April 15, 2025 |
| NCT06385522 | Not yet recruiting | Phase 1 | A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System | August 2024 | February 2027 |
| NCT04052659 | Not yet recruiting | Phase 2 | Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL | April 15, 2021 | December 30, 2025 |
| NCT06176690 | Not yet recruiting | Phase 1 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | June 1, 2024 | June 1, 2043 |
| NCT05949944 | Recruiting | Phase 1/Phase 2 | Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma | August 15, 2023 | December 2026 |
| NCT04880746 | Recruiting | Phase 3 | Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | October 17, 2020 | October 17, 2025 |
| NCT04922567 | Recruiting | Phase 2 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | April 1, 2021 | December 31, 2026 |
| NCT05083208 | Recruiting | Phase 1/Phase 2 | PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma | February 20, 2022 | January 2027 |
| NCT05441761 | Recruiting | Phase 1/Phase 2 | Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL | May 1, 2022 | May 1, 2025 |
| NCT06173999 | Recruiting | Phase 1/Phase 2 | A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma | December 22, 2023 | December 31, 2025 |
| NCT06362148 | Recruiting | Circulating Tumor DNA in Peripheral T-cell Lymphomas | March 1, 2024 | December 2030 | |
| NCT06421948 | Recruiting | Phase 1/Phase 2 | Linperlisib Combined With Chidamide in Patients With PTCL | January 1, 2024 | May 31, 2026 |
| NCT03964480 | Recruiting | Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | October 14, 2018 | July 30, 2025 | |
| NCT04234048 | Recruiting | Phase 1 | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | December 18, 2023 | November 2025 |
| NCT04480125 | Recruiting | Phase 2 | Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy | June 20, 2020 | June 20, 2024 |
| NCT04512534 | Recruiting | Phase 2 | Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma | November 13, 2020 | September 1, 2025 |
| NCT06422247 | Recruiting | Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy | June 14, 2024 | April 30, 2025 | |
| NCT01116154 | Terminated | Phase 1 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | May 2010 | August 2010 |
| NCT00101205 | Terminated | Phase 1 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2004 | |
| NCT01644253 | Terminated | Phase 1 | Phase 1b Safety and Efficacy Study of TRU-016 | September 2012 | April 21, 2021 |
| NCT04254107 | Terminated | Phase 1 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | May 29, 2020 | December 1, 2023 |
| NCT00933985 | Terminated | Phase 1 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | June 2009 | April 2013 |
| NCT01678443 | Terminated | Phase 1 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | September 1, 1999 | September 27, 2018 |
| NCT00632827 | Terminated | Phase 2 | Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) | July 1, 2008 | June 23, 2016 |
| NCT04444141 | Terminated | Phase 1/Phase 2 | A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma | May 15, 2020 | September 30, 2022 |
| NCT00441025 | Terminated | Phase 2 | The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL | September 2006 | August 2009 |
| NCT01769222 | Terminated | Phase 1 | Ipilimumab and Local Radiation for Selected Solid Tumors | February 2013 | June 2015 |
| NCT00274651 | Terminated | Phase 2 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas | January 2006 | July 2009 |
| NCT02440685 | Terminated | Phase 1/Phase 2 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | May 2015 | July 2018 |
| NCT01805037 | Terminated | Phase 1/Phase 2 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | March 5, 2013 | December 31, 2018 |
| NCT01408043 | Terminated | N/A | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | October 2011 | May 2016 |
| NCT01419795 | Terminated | Phase 2 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant | May 2012 | |
| NCT01420679 | Terminated | Phase 3 | Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients | August 2011 | December 2017 |
| NCT01841021 | Terminated | N/A | Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 | April 2014 | June 2016 |
| NCT01036399 | Terminated | Phase 2 | Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients | November 2008 | August 2011 |
| NCT03321890 | Unknown status | Phase 2 | Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | March 7, 2017 | December 31, 2020 |
| NCT04040491 | Unknown status | Phase 4 | PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma | September 1, 2019 | September 1, 2021 |
| NCT02495415 | Unknown status | Phase 2 | Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas | December 2016 | December 2021 |
| NCT02512497 | Unknown status | Phase 1 | Romidepsin Maintenance After Allogeneic Stem Cell Transplantation | December 8, 2017 | December 31, 2022 |
| NCT03000738 | Unknown status | The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas | December 2016 | December 2019 | |
| NCT04615468 | Unknown status | Phase 2 | A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） | December 1, 2020 | October 31, 2022 |
| NCT03553537 | Unknown status | Phase 3 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | June 2018 | July 2021 |
| NCT03952572 | Unknown status | Phase 3 | Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | May 10, 2019 | April 30, 2023 |
| NCT02445404 | Unknown status | Phase 2 | Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL | September 23, 2015 | June 30, 2023 |
| NCT01652014 | Withdrawn | Phase 2 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | January 2014 | January 2017 |
| NCT01355783 | Withdrawn | Phase 3 | A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma | March 2011 | November 2014 |
| NCT01769911 | Withdrawn | N/A | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | February 2015 |
- Disase is a (Disease Ontology)
- DOID:0050743
- Cross Reference ID (Disease Ontology)
- GARD:7368